Plant Name: Trichosanthes kirilowii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; ADORA3; ADORA2A; ADORA1; ADRA2C; ADRA2A; | |
| TSHR; NMUR2; | |
| GABBR1; | |
| TDP1; BLM; RECQL; PKM; ADK; GLO1; HPGD; HSD17B1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; ALOX12; NOX4; USP2; TNKS; PARP1; TNKS2; POLB; CD38; | |
| ACHE; GAA; | |
| GABRR1; | |
| CFTR; | |
| CSNK2A1; SYK; FLT3; GSK3B; MAPK1; CDK6; | |
| CA7; CA12; CA4; CA2; | |
| PPARA; PPARG; PPARD; | |
| AR; | |
| NR1I2; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS1; PTGS2; XDH; | |
| MMP12; MMP2; MMP9; | |
| TLR2; | |
| STAT6; HIF1A; TP53; | |
| KMT2A; | |
| SLC6A1; SLC28A2; SLC28A1; SLC28A3; SLC6A11; | |
| ABCC1; ABCG2; | |
| ITGAL; LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; THPO; HTT; NPC1; APP; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | ITGAL | Leukocyte adhesion glycoprotein LFA-1 alpha | P20701 | CHEMBL1803 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.549E-11 | 3.720E-08 | ADORA1, ADORA2A, ADRA2A, CA2, CA7, CD38, CDK6, CFTR, HIF1A, HTT, MAPK1, NPC1, PARP1, PTGS2, SYK, TNKS, TNKS2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.822E-10 | 2.505E-07 | ADORA2A, CA2, CA7, CFTR, HIF1A, HTT, MAPK1, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.151E-09 | 3.480E-07 | AR, BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, GLO1, KMT2A, MMP12, MMP2, MMP9, NR1I2, PARP1, PPARA, PPARD, PPARG, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.614E-09 | 1.168E-06 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 6.620E-09 | 1.550E-06 | ABCC1, ALOX12, ALOX15, ALOX5, SYK, TLR2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 9.202E-09 | 2.087E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.014E-08 | 2.253E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, NOX4, PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.905E-08 | 1.181E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.942E-08 | 1.181E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.317E-07 | 3.341E-05 | CYP1A2, CYP2A6, CYP3A4, NR1I2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.319E-07 | 7.990E-05 | CA12, CA2, CA4, CA7 |
| MF | Unclassified; | GO:0004872; receptor activity | 7.167E-07 | 8.817E-05 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, AR, ESR1, ESR2, FFAR1, FFAR4, FLT3, GABBR1, GABRR1, HPGD, ITGAL, NMUR2, NPC1, NR1I2, PPARA, PPARD, PPARG, TLR2, TSHR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.060E-06 | 2.277E-04 | CA12, CA2, CA4, CA7, CFTR |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.168E-06 | 2.325E-04 | ABCC1, ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, APP, CFTR, FFAR1, FFAR4, FLT3, GABBR1, GABRR1, NPC1, SLC28A1, SLC28A2, SLC28A3, SLC6A1, SLC6A11, TLR2, TSHR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.711E-06 | 2.797E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.711E-06 | 2.797E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2A6 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 2.897E-06 | 2.947E-04 | AR, ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 3.284E-06 | 3.263E-04 | ADORA2A, AKR1B1, CYP1A1, CYP1B1, HPGD, MAPK1, POLB, SLC6A1, STAT6, TLR2, TP53 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.426E-06 | 3.361E-04 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 3.609E-06 | 3.478E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0007610; behavior | GO:0007612; learning | 3.911E-06 | 3.751E-04 | APP, HIF1A, HTT, KMT2A, PTGS2, SLC6A1, TLR2 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 5.646E-06 | 5.232E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 7.328E-06 | 6.540E-04 | ADORA1, ADORA2A, PPARA, PPARG, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 7.994E-06 | 7.019E-04 | AKR1B1, BLM, CDK6, CFTR, CYP1B1, MAPK1, PTGS2, STAT6, TP53 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 8.461E-06 | 7.311E-04 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 8.603E-06 | 7.318E-04 | ADORA2A, APP, MAPT |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 8.603E-06 | 7.318E-04 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 8.603E-06 | 7.318E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 8.874E-06 | 7.489E-04 | ADORA1, ADORA2A, APP, CD38, KMT2A, MAPK1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 9.878E-06 | 8.147E-04 | AR, CA2, CD38, FLT3, NPC1, PARP1, PTGS2, TLR2 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.139E-05 | 9.152E-04 | AR, ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.225E-05 | 9.733E-04 | CA2, CA7, CFTR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.225E-05 | 9.733E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 1.225E-05 | 9.733E-04 | ABCC1, ABCG2, NR1I2 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.282E-05 | 1.012E-03 | AKR1B1, CYP1B1, MAPK1, MMP9, STAT6, TP53 |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 1.338E-05 | 1.043E-03 | MAPK1, MAPT, PPARA, PPARG, STAT6, SYK, TP53 |
| MF | GO:0005488; binding | GO:0001046; core promoter sequence-specific DNA binding | 1.579E-05 | 1.190E-03 | ESR1, ESR2, KMT2A, PPARG, STAT6, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.678E-05 | 1.244E-03 | AR, CYP19A1, ESR1 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.680E-05 | 1.244E-03 | FABP3, NMUR2, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 1.678E-05 | 1.244E-03 | GSK3B, HTT, MAPT |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 1.807E-05 | 1.320E-03 | CD38, CFTR, FFAR1, HIF1A, PPARD |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.037E-05 | 1.464E-03 | AR, ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 2.082E-05 | 1.487E-03 | BLM, GSK3B, HIF1A, HTT, TP53 |
| BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 2.230E-05 | 1.537E-03 | ESR1, MAPK1, STAT6 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 2.244E-05 | 1.537E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.244E-05 | 1.537E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 2.244E-05 | 1.537E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.244E-05 | 1.537E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 2.244E-05 | 1.537E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.244E-05 | 1.537E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 2.244E-05 | 1.537E-03 | SLC28A2, SLC28A3 |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 2.295E-05 | 1.556E-03 | ABCG2, ADRA2A, APP, GABBR1, GABRR1, ITGAL, SYK, TLR2, TSHR |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 2.405E-05 | 1.612E-03 | ADORA1, ADORA2A, ADRA2A, ADRA2C, HIF1A, ITGAL, PPARD, PPARG, TLR2, TP53, TTR |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 2.420E-05 | 1.617E-03 | ADORA1, ADORA2A, ADRA2C, AKR1B1, APP, CA2, CDK6, GABBR1, HIF1A, HTT, MAPK1, MAPT, PKM, PTGS2, SLC6A1, SLC6A11, SMN1, SMN2, TLR2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.526E-05 | 1.681E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 2.816E-05 | 1.845E-03 | CD38, CYP1A2, ESR1, HPGD, PTGS2, SLC6A1 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 2.889E-05 | 1.883E-03 | ADORA2A, CA2, CA7 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.013E-05 | 1.947E-03 | ABCC1, ADORA1, ADRA2A, CA2, CA4, HPGD, TSHR |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 3.097E-05 | 1.985E-03 | ADORA2A, CYP1B1, GSK3B, HPGD, HTT, MAPT, MMP9, NOX4, PPARG, PTGS2, TP53, XDH |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 3.142E-05 | 1.999E-03 | MMP2, MMP9, PPARD, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 3.984E-05 | 2.388E-03 | FABP3, FFAR1, PPARG, PTGS2, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 5.348E-05 | 3.122E-03 | FABP3, PARP1, PKM, PPARA, PPARG, TLR2 |
| BP | GO:0032501; multicellular organismal process | GO:0045986; negative regulation of smooth muscle contraction | 5.598E-05 | 3.208E-03 | ADORA1, ADRA2C, PTGS2 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 5.598E-05 | 3.208E-03 | ADORA1, ADORA2A, MAPT |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 6.429E-05 | 3.608E-03 | ADK, AKR1B1, ALOX5, AR, BLM, CDK6, CSNK2A1, ESR1, ESR2, FABP5, GSK3B, HIF1A, HPGD, HTT, KMT2A, LMNA, MAPK1, NR1I2, PARP1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, STAT6, TNKS, TP53, USP2 |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 6.512E-05 | 3.635E-03 | ADORA1, ADRA2A, CD38, PARP1, TNKS, TNKS2 |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 6.711E-05 | 3.635E-03 | APP, TLR2 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 6.711E-05 | 3.635E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.711E-05 | 3.635E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 6.711E-05 | 3.635E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 6.711E-05 | 3.635E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.711E-05 | 3.635E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 6.711E-05 | 3.635E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 6.711E-05 | 3.635E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 6.711E-05 | 3.635E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 6.711E-05 | 3.635E-03 | ADORA1, ADORA2A |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 6.774E-05 | 3.651E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 6.774E-05 | 3.651E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 7.016E-05 | 3.763E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 7.869E-05 | 4.149E-03 | ADORA1, AR, PPARA, PPARG, PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 8.101E-05 | 4.251E-03 | ADORA2A, PPARG, TP53 |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.052E-04 | 5.328E-03 | APP, MAPK1, PARP1, PTGS2, TLR2 |
| BP | GO:0065007; biological regulation | GO:0043085; positive regulation of catalytic activity | 1.161E-04 | 5.783E-03 | ADORA1, ADRA2A, ADRA2C, ALDH1A1, APP, ESR1, FLT3, GSK3B, HIF1A, MAPK1, MAPT, NMUR2, NOX4, PPARG, SYK, TNKS, TSHR, XDH |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.270E-04 | 6.207E-03 | NOX4, PARP1, POLB, TP53 |
| MF | GO:0005488; binding | GO:0043621; protein self-association | 1.270E-04 | 6.207E-03 | ACHE, FLT3, PPARG, TP53 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.338E-04 | 6.306E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.338E-04 | 6.306E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.338E-04 | 6.306E-03 | TNKS, TNKS2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 1.338E-04 | 6.306E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.338E-04 | 6.306E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.338E-04 | 6.306E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.338E-04 | 6.306E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0005332; gamma-aminobutyric acid:sodium symporter activity | 1.338E-04 | 6.306E-03 | SLC6A1, SLC6A11 |
| MF | GO:0005488; binding | GO:0032795; heterotrimeric G-protein binding | 1.338E-04 | 6.306E-03 | ADORA1, ADRA2A |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.338E-04 | 6.306E-03 | ALDH1A1, AR |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.393E-04 | 6.496E-03 | HIF1A, LMNA, PPARD, PTGS2, TP53 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.508E-04 | 6.942E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0065007; biological regulation | GO:0032409; regulation of transporter activity | 1.575E-04 | 7.190E-03 | ADRA2A, APP, CFTR, HTT, KMT2A, MMP9, PPARG |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.664E-04 | 7.579E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.728E-04 | 7.831E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 1.968E-04 | 8.624E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 2.223E-04 | 9.362E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 2.223E-04 | 9.362E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 2.229E-04 | 9.362E-03 | HIF1A, PPARD, TP53 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.223E-04 | 9.362E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 2.223E-04 | 9.362E-03 | BLM, RECQL |
| CC | GO:0043226; organelle | GO:0044454; nuclear chromosome part | 2.200E-04 | 9.362E-03 | AR, BLM, CSNK2A1, ESR1, PARP1, PPARD, STAT6, TNKS, TNKS2, TP53 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 2.323E-04 | 9.710E-03 | AR, ESR1, GSK3B, PPARA, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.731E-08 | 4.518E-06 | APP; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; PTGS2; PTGS1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.084E-07 | 6.905E-06 | HSD17B1; ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.753E-07 | 1.052E-05 | AR; GSK3B; CDK6; FLT3; MMP2; MAPK1; PPARG; PTGS2; HIF1A; TP53; MMP9; PPARD |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.957E-08 | 4.518E-06 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 6.847E-07 | 2.180E-05 | MAOA; GAA; ALOX15; ADK; AKR1B1; ALOX12; PTGS2; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2A6; PKM; HSD17B1; ALOX5; CYP1A2; ALDH1A1; CYP1A1; CD38; XDH |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.682E-07 | 1.052E-05 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 5.244E-06 | 1.002E-04 | GABBR1; GABRR1; ADORA2A; ADORA3; ADORA1; NMUR2; ADRA2C; ADRA2A; TSHR |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.384E-06 | 1.016E-04 | GABBR1; MMP2; MAPK1; ESR1; MMP9; ESR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.124E-06 | 4.507E-05 | CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.858E-06 | 1.016E-04 | FABP4; ADORA1; PTGS2; TSHR; PTGS1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 9.710E-06 | 1.427E-04 | ALOX5; ALOX15; ALOX12; PTGS2; PTGS1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.423E-05 | 1.812E-04 | PKM; FLT3; MAPK1; TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.226E-05 | 1.673E-04 | CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.725E-05 | 3.747E-04 | GABBR1; ADORA2A; ADORA1; MAPK1; PPARA; CFTR; TSHR |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.228E-05 | 4.038E-04 | MMP2; MAPK1; TP53; HIF1A; ESR1; MMP9; TLR2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.166E-05 | 2.586E-04 | CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 5.810E-05 | 5.285E-04 | CDK6; MAPK1; STAT6; TP53; MMP9; TLR2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.375E-05 | 3.747E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.837E-04 | 1.595E-03 | HPGD; KMT2A; FLT3; PPARG; TP53; MMP9 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.145E-04 | 1.781E-03 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 9.531E-07 | 2.276E-05 | CA12; CA2; CA4; CA7 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.727E-05 | 3.747E-04 | MMP2; MAPK1; MMP9; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.319E-04 | 1.846E-03 | ABCC1; ADORA3; ADORA1; MAPK1; TP53 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.417E-04 | 2.175E-03 | GSK3B; SYK; CSNK2A1; CD38; ITGAL; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.696E-04 | 2.277E-03 | POLB; CDK6; PKM; SYK; MAPK1; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.427E-04 | 2.562E-03 | ABCC1; CDK6; CYP1B1; MAPK1; PTGS2; TP53; MMP9 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.135E-04 | 2.468E-03 | GSK3B; CDK6; CSNK2A1; TP53; TLR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.884E-04 | 2.175E-03 | CYP2A6; MAOA; CYP1A2; CYP3A4 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.396E-04 | 2.175E-03 | GSK3B; MAPK1; ESR1; ESR2 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.047E-03 | 5.330E-03 | ADORA3; ADORA1; MAPK1; ADRA2C; ADRA2A |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.219E-04 | 2.175E-03 | CA2; CYP3A4; CFTR; ABCG2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 7.595E-04 | 4.145E-03 | GSK3B; AR; MAPK1; TP53 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.075E-03 | 5.330E-03 | APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 7.279E-04 | 4.089E-03 | GABBR1; GABRR1; SLC6A11; SLC6A1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 8.957E-04 | 4.752E-03 | SYK; CSNK2A1; PARP1; PTGS2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.993E-03 | 1.589E-02 | PARP1; LMNA; MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.324E-03 | 1.390E-02 | GSK3B; MAPK1; PPARA; TP53 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.908E-03 | 1.727E-02 | GSK3B; CDK6; SYK; MAPK1; TP53; TLR2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 4.199E-03 | 1.637E-02 | GSK3B; CSNK2A1; TP53; PPARD |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.348E-03 | 1.390E-02 | CDK6; MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.189E-03 | 9.955E-03 | CDK6; MAPK1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.156E-04 | 2.175E-03 | MAPK1; PPARG; TP53 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.303E-03 | 1.023E-02 | FLT3; MAPK1; PPARD |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.769E-03 | 8.239E-03 | GSK3B; MAPK1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.928E-03 | 1.271E-02 | GSK3B; MAPK1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.496E-03 | 1.421E-02 | CDK6; MAPK1; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.643E-03 | 1.673E-02 | CDK6; MAPK1; TP53 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.295E-03 | 1.641E-02 | CDK6; MAPK1; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.643E-03 | 1.673E-02 | GSK3B; SYK; MAPK1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.427E-02 | 4.325E-02 | MAPK1; PTGS2; MMP9 |
| hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 8.547E-03 | 2.767E-02 | GABBR1; GABRR1; ADORA1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 7.320E-03 | 2.497E-02 | CDK6; PTGS2; TP53 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 4.643E-03 | 1.673E-02 | MAPK1; PTGS2; TLR2 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 1.135E-02 | 3.495E-02 | GABRR1; MAPK1; PTGS2 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 7.797E-03 | 2.613E-02 | THPO; FLT3; CD38 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.156E-04 | 2.175E-03 | CYP1A2; ALOX15; CYP3A4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.357E-07 | 2.276E-05 | CYP2A6; CYP1A2; XDH |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.719E-02 | 4.974E-02 | ALOX5; MAPK1; TLR2 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 9.889E-03 | 3.148E-02 | CA2; CD38; CFTR |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.719E-02 | 4.974E-02 | MMP2; ITGAL; MMP9 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.239E-03 | 5.917E-03 | CYP2A6; CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.088E-03 | 5.330E-03 | ABCC1; CFTR; ABCG2 |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.458E-02 | 4.350E-02 | PKM; GLO1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 8.374E-03 | 2.757E-02 | GAA; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.007E-02 | 3.154E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.973E-03 | 1.727E-02 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; TP53; TP53 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; FLT3; MMP2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE; ADORA2A; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PTGS2; PPARG; PPARG; PPARD |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12; ADORA2A |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Allergic conjunctivitis | C91.0, H10, H10.45, T78.4 | ITGAL |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TLR2; FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ITGAL; ALOX5; FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD; ESR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | ITGAL; FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; MMP12; PTGS1; PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2; ADORA3 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; PPARG; PPARD; PPARD |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2; ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; ESR1; APP |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | ITGAL |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2; PPARG |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; ALOX5; SYK; PTGS2; PTGS2; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; XDH; ADRA2C |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; ALOX5; MMP12; PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; MMP12; PTGS2; ADORA2A; ADORA1; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ABCC1; ALOX5; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | SLC6A1; ADK |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ITGAL; TLR2; SYK; ADORA1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; ADK; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ADORA2A; ADRA2C; ADRA2A; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; MMP9; TP53 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH; PPARG |
| NA: NA | Geographic retinal atrophy | NA | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TLR2; PKM; SYK; FLT3; MMP2; HIF1A; MAPK1; MMP9; TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; PTGS1; ESR1 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; FFAR1; GSK3B; ADORA1; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; ESR1; ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; TLR2; CSNK2A1; SYK; FLT3; FLT3; MMP2; ACHE; PTGS2; CD38; GSK3B; ADORA3; HIF1A; MAPK1; MMP9; PARP1; TP53; ESR1; ESR1; APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Dry eye disease | H16.229 | ITGAL |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADORA3; ADORA2A; ADORA1; ADRA2C |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE; ADORA1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C; PPARG; PPARG; APP |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; CD38; TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; ACHE; CYP3A4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |